Quantitative Motor Assessment in patients with mild to moderate Alzheimer’s Disease

The University of Melbourne, AUPOA0 个研究点目标入组 40 人开始时间: 2011年3月10日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•20 cognitively healthy and age-matched control participants.
•Patients with mild-to-moderate Alzheimer’s Disease (MMSE between 10-24), both women and men, who are on stable treatment. Stable treatment means that participants will be on treatment on a stable dose (any dose) for at least six months prior to the Study Day 1 (baseline visit). Treatment can be the cholinesterase inhibitors donezepil, galantamine, rivastigmine, or the NMDA glutamate blocking drug memantine.
•Only individuals who are clinically free of extrapyramidal signs or parkinsonism to be included.

•Control participants will be used, who will be cognitively healthy (inclusion criteria - no diagnosis of dementia)
•(1) other co-existing chronic neurological diseases, (2) arthritis or orthopedic disorders, (3) active psychosis, (4) upper extremity weakness (5) incapability of following simple verbal instructions, or (6) visual or other impairments that would interfere with completion of the tasks.
•Rationale for excluding upper extremity weakness – as the experimental tasks involve gripping and tapping with the hands, we wish to exclude those with known pre-existing difficulties that would confound our results. Those with upper extremity weakness include those with weakness due to stroke, peripheral neuropathy, those with orthopaedic diagnoses, spinal cord injuries, or have any condition or reason that, in the opinion of the research team, interferes with the ability of the patient to participate in or complete the trial, which places the patient at undue risk, or complicates the interpretation of data.

发起方

The University of Melbourne, AUPOA